does semaglutide make you constipated How Long Do Side Effects Last? a Doctor's Guide The infographic compares 10 commonly

[CHUCKLES] LAURIE SUND: My pleasure

Whether due to melasma, sun damage, or post-inflammatory hyperpigmentation, many people seek treatments to achieve an even skin tone

Mayo Clinic News Network

Important safety considerations include risk of pancreatitis (stop treatment and seek urgent care if severe persistent abdominal pain radiating to the back occurs), gallbladder disease , diabetic retinopathy complications (especially with rapid improvement in blood glucose control), and risk of acute kidney injury with dehydration

Plaintiff OFA Appeals | Foley & Lardner, accessed February 2, 2026, Major Update on GLP-1 Litigation involving Compounding Pharmacies, accessed February 2, 2026, Semaglutide & Tirzepatide Patent Considerations DiversifyRx, accessed February 2, 2026, GLP-1 Drugs: FDA Removes Semaglutide from the Drug Shortage List | Foley & Lardner, accessed February 2, 2026, Out of Shortage, Into Controversy: The Fight Over GLP-1 Compounding | Pharmacy Times, accessed February 2, 2026, Despite Obesity Drug Pricing Deal, GLP-1 Compounders Continue To Operate in the Shadows BioSpace, accessed February 2, 2026, FDA Compliance Alert for Weight Management Providers: Compounded GLP-1s with Additives Montgomery Purdue, accessed February 2, 2026, GLP-1 Drugs: Ohio Board of Pharmacy Issues FAQs for Compounders | Foley & Lardner, accessed February 2, 2026, The Heavy Price of GLP-1 Drugs I-MAK, accessed February 2, 2026, Top 12 Drug Patents Expiring as early as February 2025 GreyB, accessed February 2, 2026, FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, accessed February 2, 2026, GLP-1 Litigation and the Road Ahead for Independent Pharmacies | Drug Topics, accessed February 2, 2026, FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers, accessed February 2, 2026, Beyond the Headlines: FDA Warning Letters to GLP-1 Compounders Spencer Fane, accessed February 2, 2026, Compounding Pharmacy Sues Eli Lilly, Novo Nordisk Over Alleged , accessed February 2, 2026, Compounder sues Lilly and Novo for suppressing GLP-1RA competition, accessed February 2, 2026, Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access, accessed February 2, 2026, The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026, accessed February 2, 2026, Yakym, Carson Introduce Bill to Protect Patients from Unsafe , accessed February 2, 2026, Client Alert: Recent State and Federal Legislative Developments , accessed February 2, 2026, Semaglutide shortage gives rise to unauthorized products, accessed February 2, 2026, GLP-1 Solution September 09, 2025 FDA, accessed February 2, 2026, GLP-1 Weight Loss Drug Enforcement in 2025: State Attorneys General Step into a Growing Regulatory Gap Stevens & Lee, accessed February 2, 2026, Non-Traditional Channels: The Compounded GLP-1 Market IQVIA, accessed February 2, 2026, With compounders out of the way, Lilly and Novo go after each other PharmaVoice, accessed February 2, 2026, The Great Convergence: Pharmaceuticals, Digital Health, and the Direct-to-Patient Paradigm DrugPatentWatch Transform Data into Market Domination, accessed February 2, 2026, A Strategic Guide to White Space Analysis for Pharmaceutical R&D DrugPatentWatch Transform Data into Market Domination, accessed February 2, 2026, Eli Lilly, Novo Nordisk report strong earnings as GLP-1 race heats up, accessed February 2, 2026, Patent and Innovation Trends in GLP-1 and Weight Loss Drugs (20202025): What the IP and Science Signal Next | Cypris, accessed February 2, 2026, Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices

"We really need to think about how we can tackle these issues in a more holistic way."